Update on Endometrial Cancer: From Diagnosis to Treatment

Dear Colleagues,

The knowledge of the molecular characteristics of endometrial cancer (EC) has changed profoundly in recent times. The dichotomous histologic classification (endometrial cancer types 1 and 2) proposed by Bokhman more than thirty years ago appears inadequate today. Recent genomic studies support new visions of the pathogenesis and progression of EC. Due to the early occurrence of symptoms (i.e., abnormal uterine bleeding), most women receive EC diagnosis at early stages when the disease is still confined to the uterine corpus, and they have a good prognosis after surgical treatment. The prognosis is worse for patients with high-risk EC, often experiencing cancer relapse after surgical treatment. Thus, their preoperative workup is critical for selecting patients who may need more radical surgery or adjuvant therapies. The standard treatment of EC consists of hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy; these procedures are usually performed by laparoscopic or robotic surgery. In the last decade, sentinel lymph node mapping has emerged as an attractive approach for managing patients with endometrial cancer. Conservative treatment may be considered in women with early-stage EC desiring childbearing. A better understanding of the molecular mechanisms underlying the development of EC allows for better use of current drugs and novel targeted drugs.

We encourage the submission of original manuscripts and reviews on EC.

Prof. Dr. Simone Ferrero
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.